What are the top synthetic biology startups by revenue?

Building a startup or looking for your next investment in synthetic biology? Our report gives you the full picture.
Summary
LanzaTech is currently the top synthetic biology startup by revenue in our ranking, with $55.8M of FY2025 fiscal-year revenue. Scribe Therapeutics follows with $51.2M of FY2025 fiscal-year revenue, while Generate:Biomedicines reports $31.9M of FY2025 collaboration revenue.
What makes that order interesting is what these companies sell. Carbon recycling, CRISPR engineering and AI-designed medicines all produce revenue, but customers pay them for different things.
LanzaTech earns from industrial carbon-recycling projects, products and licenses. Scribe Therapeutics and Generate:Biomedicines get paid by pharmaceutical partners for research, long before their own medicines reach patients.
That helps explain why some medical startups can bring in substantial revenue while still spending heavily on trials. A promising drug partnership can also generate headlines much bigger than the revenue recognized today.
Synthetic DNA offers a more direct route to customers. Touchlight supplies enzymatically made DNA technology, while DNA Script sells systems that let labs produce DNA themselves.
Bota Bio shows that Chinese industrial biology can also produce commercial sales. Its published annual figure lacks a clear financial period, so the current scale is harder to pin down.
Agriculture tells a similarly mixed story. Inari Agriculture has a recent segment figure, but Pivot Bio's well-known sales milestone belongs to an older financial period.
There are smaller businesses with visible buyers, too. bit.bio sells programmable human cells, Biomatter designs enzymes for industrial customers, and Spiber's fermented protein fibers have reached clothing brands.
Several famous names remain outside the ranked group. Benchling's ARR comes from one analyst estimate, while Mammoth Biosciences and Profluent have disclosed partnership amounts that cannot be counted as annual revenue.
The picture today is more commercial than the laboratory demos suggest, yet far less straightforward than a funding leaderboard. LanzaTech leads on the revenue evidence, and the biggest unanswered question for most competitors is how reliably customers will keep paying.
Written by the New Market Pitch teamWe track new markets so founders and investors can move faster. About us

In our report covering the synthetic biology market, we turn what is vague and complex into simple, useful visuals. Market maps like this one show you at a glance where every startup stands.
The ranking of top startups in the synthetic biology market by revenue
Below is a table ranking the startups of this market by their current revenue scale. You can find our methodology at the end of this page.
If you want a deeper understanding of the market and its current dynamics, get our report on the synthetic biology market.
| Ranking | Company | Latest Metric | Metric Type | Freshness | Disclosed When | Source Quality | Confidence | Segment | Why This Ranking | Local Metric | Country |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | LanzaTech | $55.8M | Fiscal-Year Revenue | Fresh · 11mo | Apr 2026 | Filed / Audited | High | Industrial Biomanufacturing & Enzymes | Its April 2026 regulatory filing records $55.8M of FY2025 fiscal-year revenue, a recent company-wide result that includes carbon-recycling work. | us | |
| 2 | Scribe Therapeutics | $51.2M | Fiscal-Year Revenue | Fresh · 11mo | Jul 2026 | Filed / Audited | High | Synthetic Biology Therapeutics | A July 2026 securities filing records $51.2M of FY2025 fiscal-year revenue. It records paid CRISPR work before the company has medicine sales. | us | |
| 3 | Generate:Biomedicines | $31.9M | Collaboration Revenue | Fresh · 11mo | Feb 23, 2026 | Filed / Audited | Medium | Synthetic Biology Therapeutics | The February 2026 SEC filing reports $31.9M of FY2025 collaboration revenue. It covers paid drug-development collaborations, not sales of its own medicines. | us | |
| 4 | Touchlight | ~$22.9M | Segment Revenue | Fresh · 11mo | Oct 13, 2026 | Filed / Audited | Medium | DNA & Genome Engineering Tools | Filed UK accounts support ~$22.9M of FY2025 segment revenue (GBP 17M). The amount covers a DNA manufacturing segment, not the entire business. | GBP 17M | gb |
| 5 | Inari Agriculture | ~$14.3M | Segment Revenue | Fresh · 11mo | Aug 25, 2026 | Filed / Audited | Medium | Engineered Crop & Cell Products | Revenue of one segment for the year to Dec 2025 from a regulatory filing. It covers only part of the year or of the business, so it is ranked as a minimum. | EUR 12.1M | us |
| 6 | Bota Bio | ~$14.1M | Annual Revenue | Period not stated · collected 35mo ago | Period not stated | Company Disclosed | Low | Industrial Biomanufacturing & Enzymes | Bota Bio itself reported ~$14.1M of annual revenue (CNY 100M), collected in December 2023 without a stated accounting period. Its reporting period is unknown, making current comparisons less reliable. | CNY 100M | cn |
| 7 | bit.bio | ~$8.17M | Fiscal-Year Revenue | Fresh · 11mo | Oct 6, 2026 | Filed / Audited | High | Engineered Crop & Cell Products | Fiscal-year revenue for the year to Dec 2025 from a regulatory filing. Ahead of DNA Script, whose figure is a partial figure. | GBP 6.07M | gb |
| 8 | DNA Script | ~$8.13M | Segment Revenue | Aging · 23mo | Dec 3, 2025 | Filed / Audited | Medium | DNA & Genome Engineering Tools | Filed French accounts show ~$8.13M of FY2024 segment revenue (EUR 7.82M). The period is older and the figure covers only part of the business. | EUR 7.82M | fr |
| 9 | Biomatter | ~$2.09M | Fiscal-Year Revenue | Fresh · 11mo | May 30, 2026 | Filed / Audited | High | Generative Protein Design Platforms | Lithuanian accounts published in May 2026 report ~$2.09M of FY2025 fiscal-year revenue (EUR 1.78M), a recent company result rather than a web estimate. | EUR 1.78M | lt |
| 10 | Spiber | ~$1.13M | Fiscal-Year Revenue | Fresh · 11mo | Mar 26, 2026 | Credible Reported | Medium | Engineered Materials & Environmental Systems | Japanese business press reported ~$1.13M of FY2025 fiscal-year revenue (JPY 177M) in March 2026. The figure is reported rather than taken from filed accounts. | JPY 177M | jp |
| NR | Benchling | $210M | ARR | Aging · 30mo | Third-Party Estimate | Low | Synbio Design & Engineering Software | Sacra estimated $210M of ARR as of May 2024. It is a single analyst estimate for a broader biotech software business, not a verified synthetic biology revenue total. | us | ||
| NR | Impossible Foods | $137M | Annual Revenue | Historical · 59mo | 2022 | Third-Party Estimate | Low | Synbio Food & Ingredients | The $137M annual revenue estimate was published in 2022, which is too old for a current rank, and the figure is third-party rather than filed. | us | |
| NR | ElevateBio | $100M | Annual Revenue | Aging · 23mo | Third-Party Estimate | Low | Synthetic Biology Therapeutics | Apps Run The World estimated $100M of 2024 annual revenue. One automated estimate without an independent match does not qualify for a rank. | us | ||
| NR | Pivot Bio | >$100M | Annual Revenue | Historical · 39mo | Aug 29, 2023 | Company Disclosed | Medium | Engineered Crop & Cell Products | The company disclosed >$100M of FY2023 annual revenue. The result is more than three years old, so strong historical sales do not set a current rank. | us | |
| NR | Perfect Day | $90.3M | Annual Revenue | Fresh · 11mo | 2026 | Third-Party Estimate | Low | Synbio Food & Ingredients | CB Insights estimated $90.3M of annual revenue for 2025. The fresh period cannot overcome the lack of a second independent estimate or company disclosure. | us | |
| NR | eGenesis | $35.1M | Annual Revenue | Fresh · 11mo | Third-Party Estimate | Low | Synthetic Biology Therapeutics | GetLatka estimated $35.1M of 2025 annual revenue. This is neither company-disclosed nor independently corroborated. | us | ||
| NR | Pairwise | $30M | Annual Revenue | Aging · 23mo | Third-Party Estimate | Low | Engineered Crop & Cell Products | Apps Run The World estimated $30M of 2024 annual revenue. A single automated company-data estimate is insufficient for a rank. | us | ||
| NR | Strand Therapeutics | $24.8M | Annual Revenue | Undated | Third-Party Estimate | Low | Synthetic Biology Therapeutics | Growjo assigns $24.8M of estimated annual revenue without a period. No company financial disclosure supports ranking the amount. | us | ||
| NR | Biomason | $24.8M | Annual Revenue | Undated | Third-Party Estimate | Low | Engineered Materials & Environmental Systems | Growjo lists $24.8M of estimated annual revenue with no stated period. Its age and accuracy cannot be verified independently. | us | ||
| NR | Elegen | $24.3M | Annual Revenue | Period not stated · collected 2mo ago | Period not stated | Third-Party Estimate | Low | DNA & Genome Engineering Tools | GetLatka gives a $24.3M automated annual revenue estimate collected in September 2026, but no financial period or independent confirmation. | us | |
| NR | Solugen | $22.2M | Half-Year Revenue | Aging · 29mo | Nov 2024 | Third-Party Estimate | Low | Industrial Biomanufacturing & Enzymes | Baillie Gifford estimated $22.2M of revenue for H1 2024. A single analyst estimate of a half-year period does not qualify for a rank. | us | |
| NR | Arbor Biotechnologies | $21.5M | Annual Revenue | Undated | Third-Party Estimate | Low | Synthetic Biology Therapeutics | Growjo estimates $21.5M of annual revenue without a stated period. The automated third-party figure is not independently confirmed. | us | ||
| NR | Air Protein | $20.5M | Annual Revenue | Undated | Third-Party Estimate | Low | Synbio Food & Ingredients | Growjo estimates $20.5M of undated annual revenue. A single automated figure cannot document current product sales. | us | ||
| NR | Asimov | $17.5M | Annual Revenue | Undated | Third-Party Estimate | Low | Synbio Design & Engineering Software | Growjo lists $17.5M of annual revenue without a stated year. It is an automated estimate, not a company disclosure. | us | ||
| NR | Geltor | $15M | Annual Revenue | Aging · 23mo | Third-Party Estimate | Low | Engineered Materials & Environmental Systems | Apps Run The World estimated $15M of 2024 annual revenue. The estimate lacks the independent second source required for a rank. | us | ||
| NR | Checkerspot | $14.7M | Annual Revenue | Undated | Third-Party Estimate | Low | Engineered Materials & Environmental Systems | Growjo estimated $14.7M of annual revenue without identifying the year. Its undated automated figure is unranked. | us | ||
| NR | ZymoChem | $13.5M | Annual Revenue | Period not stated · collected 2mo ago | Period not stated | Third-Party Estimate | Low | Engineered Materials & Environmental Systems | GetLatka estimated $13.5M of annual revenue, collected in September 2026 without a stated period. No independent estimate confirms it. | us | |
| NR | Evozyne | $10.5M | Annual Revenue | Undated | Third-Party Estimate | Low | Synthetic Biology Therapeutics | Growjo assigns $10.5M of estimated annual revenue without a reporting year. Its amount is not a verified company result. | us | ||
| NR | Samsara Eco | $8.9M | Annual Revenue | Undated | Third-Party Estimate | Low | Engineered Materials & Environmental Systems | Growjo estimates $8.9M in annual revenue without identifying a reporting period. The uncorroborated automated estimate remains unranked. | au | ||
| NR | BioConsortia | $8.8M | Annual Revenue | Undated | Third-Party Estimate | Low | Engineered Crop & Cell Products | Growjo estimates $8.8M of annual revenue without a financial period. No confirming company result supports a rank. | us | ||
| NR | BrainChild Bio | $7.8M | Annual Revenue | Fresh · 11mo | Sep 2, 2026 | Third-Party Estimate | Low | Synthetic Biology Therapeutics | GetLatka estimated $7.8M of 2025 annual revenue. Despite a recent period, it is one uncorroborated automated estimate. | us | |
| NR | GreenLight Biosciences | $6.78M | Annual Revenue | Aging · 23mo | Third-Party Estimate | Low | Engineered Crop & Cell Products | CB Insights estimated $6.78M of 2024 annual revenue. This third-party estimate has no independent corroboration. | us | ||
| NR | Allozymes | $5.9M | Annual Revenue | Undated | Third-Party Estimate | Low | Biofoundry & Automation Platforms | Growjo gives $5.9M as estimated annual revenue with no period. It does not qualify as dated, verified sales. | sg | ||
| NR | C16 Biosciences | $3.8M | Annual Revenue | Aging · 23mo | Third-Party Estimate | Low | Synbio Food & Ingredients | GetLatka estimated $3.8M of annual revenue for 2024. One automated estimate is insufficient for a revenue rank. | us | ||
| NR | Adaptyv Biosystems | ~$2.6M | Annual Revenue | Aging · 23mo | Aug 10, 2026 | Third-Party Estimate | Low | Biofoundry & Automation Platforms | An automated company-data estimate puts 2024 annual revenue at ~$2.6M. Without a second independent estimate, it remains unranked. | ch | |
| NR | Ansa Biotechnologies | $2M | Annual Revenue | Aging · 23mo | Aug 10, 2026 | Third-Party Estimate | Low | DNA & Genome Engineering Tools | GetLatka estimated $2M of 2024 annual revenue. The uncorroborated automated amount is not a company-reported result. | us | |
| NR | Chai Discovery | $1M | Annual Revenue | Aging · 23mo | 2026 | Third-Party Estimate | Low | Generative Protein Design Platforms | CB Insights estimated $1M of annual revenue for 2024. A single automated estimate is not adequate evidence for ranking. | us | |
| NR | Formo | ~$485K | Fiscal-Year Revenue | Aging · 23mo | Filed / Audited | Medium | Synbio Food & Ingredients | German filed accounts record ~$485K of FY2024 fiscal-year revenue (EUR 466K). The actual filed amount is below the ranking threshold. | EUR 466K | de | |
| NR | AMSilk | ~$170K | Fiscal-Year Revenue | Aging · 23mo | Mar 12, 2026 | Filed / Audited | Medium | Engineered Materials & Environmental Systems | German company accounts report ~$170K of FY2024 fiscal-year revenue (EUR 164K). The filed result is below the ranking threshold. | EUR 164K | de |
| NR | Aphea.Bio | ~$17K | Fiscal-Year Revenue | Fresh · 11mo | Filed / Audited | Medium | Engineered Crop & Cell Products | Belgian filed accounts report ~$17K of FY2025 fiscal-year revenue (EUR 14K). The actual revenue is below the ranking threshold. | EUR 14K | be | |
| NR | Mammoth Biosciences | $100M (other measure, not revenue) | Other Financial Metric | Historical · 31mo | Apr 25, 2024 | Company Disclosed | Medium | Synthetic Biology Therapeutics | The April 2024 Regeneron deal disclosed $100M (other measure, not revenue), combining an upfront payment with equity; that transaction cannot determine annual sales. | us | |
| NR | The EVERY Company | 2,026 orders 550% of 2025 order volume | Other Scale Signal | Fresh · 7mo | Jun 2026 | Company Disclosed | Medium | Synbio Food & Ingredients | Its Jan–April 2026 update cited 2,026 orders 550% of 2025 order volume. Orders and growth signals are not recognized revenue. | us | |
| NR | Profluent | $2.25B (contract value, not revenue) | Contract Value | Fresh · 7mo | Apr 28, 2026 | Company Disclosed | Medium | Generative Protein Design Platforms | The April 2026 Lilly agreement cited $2.25B (contract value, not revenue). Possible future milestones cannot be ranked as current revenue. | us | |
| NR | Dyno Therapeutics | $15M (contract value, not revenue) | Contract Value | Fresh · 7mo | Apr 8, 2026 | Company Disclosed | Medium | Synthetic Biology Therapeutics | Its April 2026 Astellas agreement disclosed $15M (contract value, not revenue). A license transaction does not establish annual sales. | us | |
| NR | Cradle | >50 projects | Other Scale Signal | Fresh · 11mo | Dec 12, 2025 | Company Disclosed | Medium | Generative Protein Design Platforms | In December 2025, the company described >50 projects. Those projects show customer activity but do not disclose revenue. | nl | |
| NR | 21st.BIO | ~$2.53M (other measure, not revenue) | Other Financial Metric | Fresh · 11mo | Jun 26, 2026 | Filed / Audited | Medium | Biofoundry & Automation Platforms | Danish FY2025 accounts contain ~$2.53M (other measure, not revenue), or DKK 16.1M. A different financial measure cannot be ranked as sales. | DKK 16.1M | dk |
| NR | Arzeda | >5 % Reb M market | Other Scale Signal | Fresh · 11mo | 2026 | Company Disclosed | Medium | Generative Protein Design Platforms | The company cited >5 % Reb M market in 2025. A market-share claim is not a monetary revenue figure. | us | |
| NR | Abiochem Biotechnology | >50K enzyme library | Other Scale Signal | Very Fresh · 2mo | Company Disclosed | Medium | Industrial Biomanufacturing & Enzymes | Its September 2026 company profile described a >50K enzyme library. Library size says nothing definitive about annual revenue. | cn |

Our research about synthetic biology gets updated several times a month, so you always get the latest view of where things stand.
Are synthetic biology startups making real money yet?
Yes, synthetic biology startups already sell carbon-recycling technology, CRISPR research, DNA tools and engineered cells.
LanzaTech works with industrial customers, Scribe Therapeutics earns research income from drug-development partners, and Touchlight supplies enzymatically manufactured DNA. These are businesses with paying customers, although a carbon-derived chemical and a pharmaceutical research contract tell us very different things about market demand.
Consider Generate:Biomedicines. Its filings describe collaboration revenue from work with pharmaceutical partners, while its own medicines have not yet produced product sales. bit.bio faces customers much sooner in the process: researchers order standardized human cells for experiments. Its latest company update reports more paid cell shipments, orders and active customers. Those operating measures help show that people keep buying, even though they cannot replace the company's reported revenue figure.
The business models differ mainly in how customers pay: some fund research stages, while others keep ordering products. Both can make money today. We just should not assume the same revenue number means the same kind of business.
Does the best-funded synthetic biology company also sell the most?
No, a synthetic biology startup can raise a fortune without earning comparable revenue from customers.
Drug discovery, industrial fermenters and engineered-cell factories cost money years before sales arrive. The biggest venture rounds therefore tell us what investors are betting on, not what a business is selling today.
Look at Profluent's agreement with Eli Lilly. The announced maximum includes potential payments tied to future progress, so it cannot stand in for annual revenue. Mammoth Biosciences signed a Regeneron agreement with an upfront payment and an equity investment. Cradle has described active projects and major pharmaceutical customers, but has not published a comparable revenue figure in this comparison.
LanzaTech's revenue, Scribe Therapeutics' collaboration income and DNA Script's DNA technology sales come from different sources and business models. At least they are tied to identified accounting periods. Funding figures and contract ceilings give us no way to decide which startup earns more from its work. A highly funded company may become the larger business later, but its bank balance cannot answer this revenue question now.

In our market report about synthetic biology, we look at what the winners do differently, so you can learn from the best instead of guessing.
Is LanzaTech still earning significant money from carbon recycling?
Yes, LanzaTech remains the synthetic biology revenue leader on the strength of its latest full-year financial filing.
The company engineers microbes to convert waste carbon into useful chemicals. Its annual report also shows that customers pay for more than finished molecules: revenue includes products, services, collaboration work and licensing.
The mix makes the results worth reading closely. LanzaTech's 2025 filing showed recurring revenue growing while one-time revenue fell. The company's total revenue increased compared with the previous year, partly helped by a licensing arrangement and additional CarbonSmart product sales. Repeat customer activity is encouraging, but licensing payments can cause sharp changes from one quarter to the next.
LanzaTech's August 2026 update showed continuing revenue alongside efforts to cut costs. That matters for the next test: the company has proved it can sell carbon-recycling technology, but it still needs to make the business pay for its operating costs. It listed publicly in 2023. Its current revenue position is clear, but long-term profitability remains a separate question.
Is Scribe Therapeutics making real money from CRISPR yet?
Scribe Therapeutics earns substantial synthetic biology revenue from CRISPR partnerships, although it has not built a mass-market drug-sales business.
Scribe engineers gene-editing systems for medicines intended to prevent or treat disease. Its reported FY2025 fiscal-year result comes from a regulatory filing, which makes the sales evidence stronger than a funding headline or an automated estimate.
The company started trading on Nasdaq in July 2026. Its later financial updates described research collaborations and a pipeline aimed at cardiovascular targets such as LDL cholesterol and lipoprotein(a). Those programs help explain what partners are paying Scribe to develop. They also show why an existing collaboration can generate revenue years before the final medicine reaches patients.
There is a catch. In 2026, Scribe reported a decline in collaboration revenue against the comparable previous-year quarter. Partner-funded research changes as programs advance, pause or finish, so an impressive fiscal year does not guarantee the same pace every quarter. Scribe's position near LanzaTech reflects real reported income. The two companies still depend on completely different ways of getting paid.

In our document detailing everything you need to know about synthetic biology, you will always find fresh funding data, taken straight from our own verified funding database.
Why does Generate:Biomedicines earn money before selling medicines?
Generate:Biomedicines gets paid to design therapeutic proteins for pharmaceutical partners while developing its own drugs.
Its FY2025 figure represents collaboration revenue, not medicine sales. That distinction is explicit in the company's SEC prospectus, which also says its own pipeline has not yet generated product revenue.
Amgen and Novartis have worked with Generate on protein therapeutics for selected targets. Generate recognizes research revenue as it performs the agreed work. A larger possible milestone payment stays outside recognized sales until the relevant conditions are met. We can therefore see commercial demand for the design platform without assuming a drug has been approved or sold.
The company went public in early 2026. Later filings continued to describe pharmaceutical partnerships alongside costly clinical development. Generate still needs to renew and expand its partner work while advancing medicines of its own. Scribe Therapeutics faces a related challenge with CRISPR collaborations, and Mammoth Biosciences has a partnership whose disclosed transaction amount also should not be treated as annual sales. In genetic medicine, getting paid for research is a real business, but recurring medicine sales would change the economics considerably.
Which synthetic biology products are already bringing in sales?
Synthetic biology startups currently get paid for industrial chemicals, drug research, synthetic DNA, agricultural engineering, human cells and enzymes.
The customer is usually easier to understand than the technology. Drugmakers pay Scribe Therapeutics and Generate:Biomedicines to engineer biological tools for treatment programs. Touchlight supplies DNA manufacturing technology, while DNA Script puts DNA synthesis systems inside laboratories. Inari Agriculture develops engineered crop traits, and bit.bio ships programmed human cells to researchers.
These products also explain why the reported figures need their original labels. Bota Bio publishes annual revenue without a stated reporting period. Touchlight and Inari Agriculture have segment figures, and DNA Script's reported segment period is older than many of the others. A fiscal-year total measures something different from a segment's sales, even if both reflect customer demand. Inari Agriculture ranks just above Bota Bio, and bit.bio just above DNA Script, by small margins: figures reported in euros, pounds or yuan are converted at the exchange rate at the end of each reporting period, so a currency move can be enough to swap two close neighbors.
The table below shows seven synthetic biology startups from different product categories, kept in revenue-rank order.
| Company | Figure | Revenue basis | Period |
|---|---|---|---|
| Touchlight | ~$22.9M | Segment Revenue | FY2025 |
| Inari Agriculture | ~$14.3M | Segment Revenue | FY2025 |
| Bota Bio | ~$14.1M | Annual Revenue | Period not stated |
| bit.bio | ~$8.17M | Fiscal-Year Revenue | FY2025 |
| DNA Script | ~$8.13M | Segment Revenue | FY2024 |
| Biomatter | ~$2.09M | Fiscal-Year Revenue | FY2025 |
| Spiber | ~$1.13M | Fiscal-Year Revenue | FY2025 |

Learning from others' mistakes is the cheapest lesson there is. In our report covering the synthetic biology market, we look at what broke startups before you, so you don't repeat it.
Has Touchlight turned synthetic DNA manufacturing into a business?
Yes, Touchlight has commercial revenue from enzymatically manufactured DNA, including a filed FY2025 segment result.
Touchlight makes doggybone DNA, a closed DNA template used in areas such as mRNA production and genetic medicines. That is a product drug developers can use in manufacturing, not just a laboratory demonstration.
Pfizer signed a patent-license agreement with Touchlight in 2022. The arrangement included an upfront payment and possible later royalties and milestones. That tells us how a DNA technology supplier can make money before a partner's drug reaches the market. The filed segment figure adds financial evidence beyond the announcement itself, but it covers a defined part of operations rather than an unrestricted whole-company total.
DNA Script is taking a different approach to the same need. Its SYNTAX platform lets laboratories synthesize DNA on site instead of ordering every sequence from a supplier. Touchlight supplies manufacturing technology and intellectual property, while DNA Script sells the equipment and chemistry for local production. Both have customers, but neither agreement announcements nor product launches tell us how often those customers buy again.
Is DNA Script turning its DNA printers into meaningful sales?
DNA Script has recorded synthetic DNA sales, but its available financial figure comes from a FY2024 segment filing.
Its SYNTAX platform lets researchers make DNA when they need it, rather than waiting for an outside supplier. That makes the value proposition easy to understand for laboratories that run frequent experiments or need rapid iteration.
DNA Script widened distribution in Latin America and East Asia in March 2026 and later announced another partner in India. These channels could reach more buyers. They do not tell us how many machines have shipped or how much reagent revenue followed. An August 2026 announcement also put the company in a GE HealthCare-led project supported by ARPA-H to develop distributed DNA manufacturing. That program tests another application for the same technology, without providing a new annual sales figure.
Touchlight's DNA licensing and supply business shows a second way to earn from enzymatic synthesis. For now, DNA Script's reported revenue establishes that its technology has been commercialized, while the newer distribution news describes opportunity rather than measured sales growth.

In our research about synthetic biology, we always try to gather several sources and make estimates that make sense, so you can work with solid numbers.
Can China's synthetic biology factories make money yet?
Yes, China's Bota Bio has disclosed annual sales from industrial synthetic biology products and biomanufacturing.
Bota Bio began building a biofoundry in 2020, delivered an early commercial project in 2022, and introduced a nisin biopreservative and a manufacturing site in 2023. Its work spans products used in food and personal care, where a producer needs to deliver useful ingredients reliably instead of only proving that engineered microbes work in a lab.
The financial evidence needs care. Bota's website identifies a commercial revenue milestone around December 2023, yet the annual figure does not state which accounting year it covers. It is a company disclosure rather than an outside estimate, but we cannot treat it like a freshly filed fiscal-year result.
Inari Agriculture's newer filed segment result, which ranks just above Bota's figure, is useful context because it shows how differently biological businesses disclose sales. A factory opening or a partnership announcement cannot stand in for revenue that was never published. Bota has moved into products, but the current size of those sales is less certain.
Are gene-edited seeds already earning revenue?
Inari Agriculture already earns revenue from gene-edited crop work, although its published figure covers only a segment.
Inari's SEEDesign platform combines crop genetics, modeling and targeted edits. The goal is to improve traits farmers already care about, from yield to resilience. The product development cycle is long: a successful genetic edit must survive field testing, seed multiplication and commercial distribution before it reaches growers.
Inari's company timeline describes field trials and a commercial-ready soybean design tested in 2025. Canada's official listings also include Inari gene-edited soybean entries. These are concrete steps toward commercial use, but a trial or regulatory entry is not itself a sale.
Pivot Bio operates at a different point in the farm supply chain. Its engineered microbes are agricultural inputs that growers can apply during planting rather than genetics built into seed varieties. Both approaches create products for farmers, but the purchase and replacement cycles differ. Inari's filed revenue demonstrates commercial activity today, but the broader crop pipeline still has to turn repeated field results into repeated customer purchases.

If you build or invest in the synthetic biology market, you need to know which business models pay off now and which ones are fading. That's why our report covering it has a whole section on it.
Is Pivot Bio already a big business in agricultural synthetic biology?
Yes, Pivot Bio disclosed >$100M of FY2023 annual revenue from engineered agricultural microbes, but that figure is now historical.
That older sales milestone is real company evidence. But it is more than three years old, so it does not show how much Pivot Bio earned in a more recent fiscal year.
Pivot sells nitrogen-fixing microbial products to farmers. In March 2025, it introduced a new generation of PROVEN products. Its 2026 materials discuss field tests and arrangements meant to give growers more predictable access to supplies. These announcements matter because farmers can test whether a microbial treatment improves their crop economics and decide whether to buy again next season.
They cannot tell us how much revenue those later seasons produced. Inari Agriculture offers a useful contrast: its more recent filed segment result has a narrower business scope, while Pivot's stronger historical milestone is too old for a current rank. The companies both work in agricultural synthetic biology, but recent revenue must be established from a recent financial period. Pivot's product footprint alone cannot fill that gap.
Are American synthetic biology startups earning more than European ones?
American synthetic biology startups hold the highest reported revenue positions today, but the published figures do not prove a US lead across the entire industry.
LanzaTech, Scribe Therapeutics and Generate:Biomedicines have dated financial statements or regulatory disclosures. Their businesses include industrial carbon recycling and paid medical research, both of which can produce substantial recognized revenue before a finished product reaches a broad consumer market.
Europe has different commercial examples. Touchlight manufactures DNA in the UK, DNA Script develops enzymatic DNA production in France, bit.bio sells programmed cells from the UK, and Lithuania's Biomatter designs enzymes used by large industrial customers. Recent updates from DNA Script, bit.bio and Biomatter describe distribution deals, higher paid-cell volumes and enterprise customers. Those facts support real demand, even when they are not new revenue totals.
We cannot turn such a mixed set of company statements into a national sales census. The more defensible observation is narrower: the largest current published figures in this comparison are American, while European startups have established paying businesses in tools, cells and enzymes. The difference may partly reflect which firms disclose their accounts and what those accounts measure.
Are programmable human cells a viable business for bit.bio?
Yes, bit.bio has a real synthetic biology business selling standardized human cell models to laboratories and drug developers.
Its FY2025 fiscal-year revenue is documented in UK accounts. Researchers use the company's programmed cells to test compounds and study diseases without building every model from scratch, which gives customers a reason to order more than once.
The company's commercial updates are unusually useful. In September 2026 it announced a partnership to broaden its cardiac-cell portfolio. In November, bit.bio reported paid vial volumes up 76% year to date, orders up 34% and active customers up 40%. All three figures come from the company and describe customer activity, not fiscal-year revenue growth. They show that more people were buying and using its cell models during the period.
For bit.bio, recurring lab orders are the important test. A research collaboration can bring in a large payment once, while standardized cell vials can be bought across many experiments. The annual filings show that revenue exists, while the recent shipment and customer updates make continued demand more believable. Profitability and long-term scale are still separate tests.

In our document detailing everything you need to know about synthetic biology, we don't want to repeat what boring consulting reports say. Instead, we show you the real and latest market signals that matter.
Do AI-designed enzymes have paying customers yet?
Biomatter already sells AI-designed enzymes to industrial customers, with both filed revenue and named product uses.
Biomatter uses computational design and laboratory testing to create proteins for specific industrial tasks. Its FY2025 fiscal-year result is available through Lithuanian accounts, which gives a more reliable starting point than an AI-platform valuation or funding headline.
A recent Invest Lithuania announcement reported more than 50 custom enzymes delivered to more than 25 enterprise customers. The company named clients including AstraZeneca, BASF, Sanofi, Kirin Holdings and Neogen. One Biomatter-engineered enzyme also appears in Thermo Fisher Scientific's SuperScript V reverse transcriptase product, where better resistance to oxidation helps during handling and shipping. That is an example of AI-guided protein design making it into a product a lab can actually buy.
Biomatter also announced a Series A and plans for a larger design-and-testing facility in Vilnius. Those plans can increase capacity, but the existing enzymes and customer relationships are the stronger evidence of commercialization. The remaining question is how often customers return with new work and how much that expands recognized revenue.
Does selling clothing mean Spiber is making a lot of money?
No, Spiber's fermented protein fibers have reached fashion brands, but those product launches have not produced large reported synthetic biology revenue.
Spiber makes Brewed Protein fibers using engineered biological production. Goldwin and The North Face have featured the material, while Spiber has also announced collaborations involving Stella McCartney and ISSEY MIYAKE. These are recognizable retail products, so the challenge has moved beyond proving that the material can be made.
But the clothing brand's retail price is not Spiber's revenue. A fabric maker must produce protein, process it into fiber and meet consistent quality and cost targets before large fashion customers can order at scale. A limited collection can prove that the material works and still involve relatively small volumes.
Tokyo Shoko Research's FY2025 report supplies a fiscal-year sales figure for Spiber, the smallest of the ten synthetic biology startups with a ranked revenue figure. That number is more useful for judging current commercial scale than counting product collaborations. Spiber has customers and finished goods. Scaling production at an acceptable cost is the harder next step.

In our report covering the synthetic biology market, we like to show you the big picture. We know your time is precious, so we make every page quick to read and packed with as much learning as possible per minute.
Is Impossible Foods one of the biggest synthetic biology earners?
Impossible Foods sells real food, but its old revenue estimate cannot establish a current synthetic biology revenue position.
Its published figure relates to 2021 and comes from a third-party estimate, rather than a recent company filing. Impossible Foods also sells a full range of consumer foods, so total company sales cover more than the specific engineered biological ingredient that puts it in this market.
Other animal-free food companies raise the same issue in different ways. Perfect Day makes fermentation-derived dairy proteins but appears here through an automated revenue estimate. The EVERY Company has publicized a sharp increase in orders for its egg-protein business, which says something about demand but gives no recognized annual sales figure. Food producers also need to compete on price, taste, reliability and supply against conventional ingredients. Passing a technical test in a fermenter does not guarantee a profitable grocery product.
Impossible Foods belongs in the discussion because consumers recognize its products. A precise current rank, however, would require recent revenue for the relevant business on the same evidentiary footing as the companies with audited or filed results.
Is Benchling making more money than synthetic biology lab startups?
Benchling may have a large life-science software business, but its ARR estimate cannot establish a current synthetic biology revenue lead.
Sacra estimated $210M of ARR as of May 2024. ARR means annual recurring revenue, and this number is an analyst estimate rather than a confirmed company disclosure. Benchling also serves a much broader biotech market, without a separately published synthetic biology segment in our comparison.
Those are two different reasons to avoid assigning it a rank. A software subscription can renew more predictably than a one-off molecular design project, but an estimated subscription total for all biotech customers should not be treated as measured revenue solely from synthetic biology. Impossible Foods has an old company-wide estimate, Pivot Bio has a historical company sales disclosure, and Perfect Day and ElevateBio appear through uncorroborated automated estimates. None establishes a current directly comparable position.
The table below shows six well-known businesses and the specific figure each has disclosed or been assigned, without treating them as ranked sales totals.
| Company | Figure | Evidence | Period |
|---|---|---|---|
| Benchling | $210M | ARR | May 2024 |
| Impossible Foods | $137M | Annual Revenue | 2021 |
| ElevateBio | $100M | Annual Revenue | 2024 |
| Pivot Bio | >$100M | Annual Revenue | FY2023 |
| Perfect Day | $90.3M | Annual Revenue | 2025 |
| eGenesis | $35.1M | Annual Revenue | 2025 |
Benchling's ARR is an analyst estimate; Pivot Bio's disclosed revenue is historical. The other figures here are third-party estimates, and Impossible Foods' period is historical.

When you build or invest in the synthetic biology market, you need clarity, not confusion. In our research about synthetic biology, we always try to put numbers on and quantify whatever is usually vague and confusing.
Does Profluent's Lilly partnership mean it has billion-dollar revenue?
No, Profluent's agreement with Eli Lilly is a potential multiyear deal, not evidence of billion-dollar annual synthetic biology sales.
The announced $2.25B is contract value tied to possible future payments, not recognized revenue. Profluent designs biological proteins with AI, and the Lilly agreement gives the drugmaker access to engineered recombinases that might eventually help create genetic medicines.
The terms included research funding, a payment at signing, possible milestones and royalties. Those money streams arrive under different conditions. Some may never be earned, depending on whether the work reaches the agreed targets. Generate:Biomedicines provides a useful comparison because its SEC reports show collaboration revenue being recognized as research is performed. Mammoth Biosciences' agreement with Regeneron also bundled upfront cash with equity investment, which should not be counted as one year of sales.
Lilly's willingness to sign the agreement is commercially meaningful. It shows that Profluent has technology a major drugmaker wants to explore. It tells us much less about Profluent's present revenue, so the company remains unranked until an eligible figure is disclosed.
Is Mammoth Biosciences already earning $100M from CRISPR?
Mammoth Biosciences has not disclosed annual CRISPR revenue at the level its Regeneron deal headline might suggest.
The April 2024 agreement covers work on gene-editing medicines using Mammoth's compact CRISPR systems and Regeneron's delivery technology. Regeneron's announcement separated the cash payment from its purchase of an ownership stake, with additional potential milestones and royalties if the programs succeed.
Regeneron bought an ownership stake in Mammoth. That gave the startup capital, while research payments are recognized under different accounting rules. A future milestone also depends on an event that may never happen. Dyno Therapeutics announced an Astellas license for an engineered gene-delivery capsid in April 2026. That agreement gives evidence of a paying pharmaceutical relationship without automatically establishing an annual sales level.
Generate:Biomedicines, by contrast, publishes recognized collaboration revenue in SEC filings. Mammoth has major pharmaceutical partners and potentially valuable technology, but its transaction announcement does not tell us what the company earned over a full financial year. A revenue ranking needs that distinction.

A good product starts with a real problem. In our report covering the synthetic biology market, we show you the ones customers still live with.
Can synthetic biology's top sellers become profitable businesses?
Synthetic biology's highest-revenue startups have paying customers, but profitability remains unproven for many of the best-known companies.
LanzaTech's 2025 annual report recorded a net loss even as its reported revenue rose. The company has since stressed spending cuts. Industrial biology has to pay for manufacturing, facilities and deployment, so winning customer work can still leave the business losing money.
Therapeutics companies face a different bill. Generate:Biomedicines earns from pharmaceutical collaborations while paying to develop and test its own medicines. Scribe Therapeutics also depends on partner-funded research programs whose revenue can change as projects progress. Even when partners pay, these businesses may need years of further spending before products produce royalties or sales.
DNA Script, bit.bio and Biomatter avoid some clinical-trial costs by selling tools, cells or enzymes that researchers can use today. Still, they must pay for quality control, production and customer support. The current figures prove that synthetic biology can bring in revenue. They cannot, by themselves, tell us which model will consistently earn more than it costs to operate.
So, which synthetic biology startups make the most money today?
LanzaTech is the top synthetic biology startup by revenue today, followed by Scribe Therapeutics and Generate:Biomedicines.
The leading companies earn from industrial carbon recycling and paid biotechnology research. Touchlight and DNA Script show another path through enzymatic DNA, while Inari Agriculture, Bota Bio, bit.bio, Biomatter and Spiber have reported activity across manufacturing, farming, cells, enzymes and materials.
Several famous companies stay outside the ordered list for specific reasons. Pivot Bio's figure is too old, Benchling's ARR is a single analyst estimate for a broader business, and the large Profluent and Mammoth partnership announcements are deal terms rather than recognized annual sales. We keep their commercial achievements in view without turning an estimate or a possible milestone into a current revenue position.
The table below shows what we found.
| Question | Answer |
|---|---|
| Is industrial biology already a sales business? | Yes, LanzaTech leads synthetic biology revenue on reported financial results. Its FY2025 fiscal-year revenue reached $55.8M in a filing. That success still came with a reported net loss. |
| Can CRISPR collaborations bring in major revenue? | Yes, Scribe Therapeutics already earns meaningful income from research partners. Its FY2025 fiscal-year revenue was $51.2M in regulatory filings. The company has not turned that into approved medicine sales. |
| Do protein platforms earn money before approval? | Yes, Generate:Biomedicines gets paid for protein-design research by pharmaceutical partners. Its FY2025 collaboration revenue was $31.9M in SEC filings. Its own pipeline has not yet produced drug sales. |
| Are synthetic DNA makers selling useful products? | Yes, Touchlight earns from manufacturing technology used in genetic medicines. Its FY2025 DNA segment revenue was ~$22.9M in filed accounts. That figure covers a segment rather than all operations. |
| Can engineered microbes already generate industrial sales? | Yes, Bota Bio has disclosed sales of industrial biomanufacturing products. Its published annual revenue figure is ~$14.1M without a stated period. That missing date weakens the picture of current scale. |
| Are gene-edited crops earning money for developers? | Yes, Inari Agriculture has a published agricultural engineering revenue figure. Its FY2025 segment revenue was ~$14.3M in filed accounts. Broader field trials cannot be counted as additional sales. |
| Can DNA printers reach paying research laboratories? | Yes, DNA Script has commercialized enzymatic DNA synthesis equipment and technology. Its FY2024 segment revenue was ~$8.13M in French accounts. New distribution deals have not yet supplied newer sales figures. |
| Are programmable human cells attracting repeat buyers? | Yes, bit.bio reports stronger demand for standardized human cell models. Paid vial volumes rose 76% year to date in 2026. Those shipments are evidence of demand, not recognized annual revenue. |
| Does AI enzyme design already have customers? | Yes, Biomatter has engineered enzymes for large industrial customers. Its recent announcement named more than 25 enterprise customers. Customer counts still cannot replace the company's fiscal-year accounts. |
| Do big CRISPR deals equal annual revenue? | No, Mammoth Biosciences' deal combined an upfront payment with equity. Its $100M Regeneron transaction was not an annual revenue disclosure. Part of that amount represented an investment in the startup. |
| Can a contract ceiling prove biology market leadership? | No, Profluent's Lilly announcement described payments dependent on future progress. Its $2.25B figure was contract value rather than recognized revenue. Until income is disclosed, it cannot receive a revenue rank. |

In our document detailing everything you need to know about synthetic biology, we try to remove everything that could confuse you, especially if you're investing or building in this market.
Our methodology
Our data runs through November 14, 2026. We define synthetic biology as deliberate design, construction or reprogramming of biological sequences, enzymes, cells, organisms and engineered biological production systems. We include programmable genome tools, biological manufacturing, engineered crops, cell models, protein design linked to biological validation, and boundary cases rather than omitting them automatically. Every ranked company meets our fixed startup definition: founded in 2000 or later, innovation-led, growth-oriented and independent, either unlisted or listed within the past five years. Established corporate groups are excluded even where they earn more.
We searched company announcements, investor materials, annual reports, regulatory filings and reputable press across the past ten years, recording the period and the meaning of each reported figure. Companies reveal scale in very different ways. We never transformed ARR into annual recognized revenue, converted a contract ceiling into sales, or built revenue figures from customer counts, estimated prices, bookings, GMV or projections.
For each company, we retained one figure, preferring a period ending within eighteen months, then direct filings or company disclosures ahead of press reports, analyst assessments and automated company-data estimates. Within equally suitable evidence, full-year revenue takes priority over ARR or run-rate, followed by partial-period or segment revenue. We order the eligible figures as recorded, using a geometric midpoint for a range and the lower bound for a stated minimum. A figure older than three years, a forecast or a metric that is not revenue is displayed without a rank.
Freshness labels are Very Fresh, Fresh, Aging and Historical, based on elapsed time since the period ends. High confidence means a recent exact annual result published by the company or in a filing; Medium covers ARR, run-rates, partial or segment figures, press disclosures, minimums or observations eighteen to thirty months old; Low covers estimates, broad ranges and older observations. Original non-dollar currencies are retained and displayed alongside US-dollar equivalents calculated using fixed exchange rates. A single analyst or automated estimate receives no rank; two independent estimates in agreement may rank at Low confidence, while conflicting estimates appear as an unranked range. A company disclosure without a stated period can rank at Low confidence, but an undated estimate cannot.
We also exclude whole-company sales from a ranking when the company operates beyond synthetic biology and the relevant market segment has not been published. That safeguard particularly matters for broad life-science software, food and diversified biotechnology companies. A business with no eligible revenue figure may still be discussed through a contract, a product launch or customer activity, but these measures remain explicitly separate from recognized income.
The obvious objection is that this method places different kinds of income in one ordered list. We do that deliberately because the title asks who is earning money with synthetic biology, not who has the cleanest subscription accounts. We expose each figure's source, time period, scope and confidence so readers can distinguish a reliable fiscal-year filing from a partial segment or older disclosure. A famous company without an eligible number stays unranked; apparent precision does not justify inventing a current revenue position.
Key sources include LanzaTech FY2025 filing, revenue components and operating performance, LanzaTech August 2026 business and cost-reduction update, Scribe Therapeutics 2026 SEC quarterly filing, IPO and collaboration income, Scribe Therapeutics 2026 CRISPR pipeline and listing update, Generate:Biomedicines FY2025 filing and collaboration revenue, Generate:Biomedicines 2026 results and partner program disclosures, Touchlight and Pfizer DNA manufacturing license announcement, Bota Bio's production, products and revenue milestone timeline, Inari Agriculture seed editing and field-trial milestones, Canadian official entries for Inari gene-edited soybean products, DNA Script's March 2026 distribution expansion, DNA Script participation in ARPA-H distributed DNA program, bit.bio November 2026 paid-vial, customer and order metrics, bit.bio September 2026 human cardiac cell partnership, Biomatter November 2026 customer, product and facility announcement, Spiber's 2025-2026 fashion products and partner-platform launches, Pivot Bio agricultural microbial product launch, Pivot Bio's 2026 farm studies and multiyear supply program, Regeneron and Mammoth Biosciences transaction terms, Profluent and Lilly engineering collaboration and possible milestones, Dyno Therapeutics' April 2026 Astellas license, and Cradle's December 2025 pharmaceutical customer and project disclosure.

Learning from others' mistakes is the cheapest lesson there is. In our report covering the synthetic biology market, we look at what broke startups before you, so you don't repeat it.
Written by the New Market Pitch teamWe track new markets so founders and investors can move faster. About us
